52
Participants
Start Date
October 31, 2007
Primary Completion Date
March 31, 2009
Study Completion Date
May 31, 2009
Degarelix
Two doses of 16 mg each administered as two administrations (separated by 14 days) will be evaluated for 42 days.
Degarelix
One dose of 32 mg administered as a single administration will be evaluated for 42 days.
Degarelix
Two doses of 32 mg each administered as two administrations (separated by 14 days) will be evaluated for 42 days.
Degarelix
One dose of 64 mg administered as a single administration will be evaluated for 42 days.
CRS Clinical Research Services Monchengladback GmbH, Mönchengladbach
Lead Sponsor
Ferring Pharmaceuticals
INDUSTRY